Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2704-2709

  Roberts, Jason A ^a   Taccone, Fabio Silvio ^b   Udy, Andrew A ^a   Vincent, Jean Louis ^b   Jacobs, Frédérique ^b   Lipman, Jeffrey ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIAZEPAM; VANCOMYCIN;

ADULT; ARTICLE; BODY SURFACE; BODY WEIGHT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SEPSIS; URINALYSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 79956324640     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01708-10     Document Type: Article

References (33)

1. Bauer, L. A., D. J. Black, and J. S. Lill. 1998. Vancomycin dosing in morbidly obese patients. Eur. J. Clin. Pharmacol. 54:621-625.
2. Beal, S. L., and L. B. Sheiner. 1998. NONMEM user guides (I-VIII). University of California at San Francisco, San Francisco, CA.
3. Blot, S. I., K. H. Vandewoude, E. A. Hoste, and F. A. Colardyn. 2002. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch. Intern. Med. 162:2229-2235.
4. Burton, D. C., J. R. Edwards, T. C. Horan, J. A. Jernigan, and S. K. Fridkin. 2009. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 301:727-736.
5. De Backer, D., et al. 2010. Comparison of dopamine and norepinephrine in the treatment of shock. N. Engl. J. Med. 362:779-789.
6. del Mar Fernandez de Gatta Garcia, M., N. Revilla, M. V. Calvo, A. Dominguez-Gil, and A. Sanchez Navarro. 2007. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med. 33:279-285. (Pubitemid 46221233)
7. DeRyke, C. A., and D. P. Alexander. 2009. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp. Pharm. 44:751-756.
8. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
9. Finfer, S., et al. 2004. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 30:589-596. (Pubitemid 38530093)
10. Garnacho-Montero, J., et al. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31:2742-2751.
11. Giuliano, C., K. K. Haase, and R. Hall. 2010. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. Expert Rev. Anti Infect. Ther. 8:95-106.
12. Hardy, K. J., P. M. Hawkey, F. Gao, and B. A. Oppenheim. 2004. Methicillin resistant Staphylococcus aureus in the critically ill. Br. J. Anaesth. 92:121-130.
13. Ho, K. M., and J. O. Robinson. 2009. Risk factors and outcomes of methicillin- resistant Staphylococcus aureus bacteraemia in critically ill patients: a case control study. Anaesth. Intensive Care 37:457-463.
14. Jeffres, M. N., et al. 2006. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia. Chest 130:947-955.
15. Jeurissen, A., I. Sluyts, and R. Rutsaert. 2011. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int. J. Antimicrob. Agents 37:75-77.
16. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
17. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
18. Kumar, A., et al. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34:1589-1596.
19. Llopis-Salvia, P., and N. V. Jimenez-Torres. 2006. Population pharmacokinetic parameters of vancomycin in critically ill patients. J. Clin. Pharm. Ther. 31:447-454.
20. Marik, P. E. 1993. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth. Intensive Care 21:172-173. (Pubitemid 23132762)
21. Matthews, I., C. Kirkpatrick, and N. Holford. 2004. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br. J. Clin. Pharmacol. 58:8-19.
22. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.
23. Parke, J., N. H. Holford, and B. G. Charles. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59:19-29.
24. Pea, F., et al. 2009. Prospectively validated dosing nomograms for maximising the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob. Agents Chemother. 53:1863-1867.
25. Pea, F., L. Porreca, M. Baraldo, and M. Furlanut. 2000. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J. Antimicrob. Chemother. 45:329-335.
26. Potoski, B. A., and D. L. Paterson. 2007. Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumonia. Chest 132:1101-1103.
27. Roberts, J. A., and J. Lipman. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37:840-851.
28. Rybak, M., et al. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
29. Rybak, M. J. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl. 1):S35-S39.
30. Rybak, M. J., et al. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327.
31. Udy, A. A., J. A. Roberts, R. J. Boots, D. L. Paterson, and J. Lipman. 2010. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet. 49:1-16.
32. Vincent, J. L., et al. 1998. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit. Care Med. 26:1793-1800.
33. Wysocki, M., et al. 2001. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45:2460-2467.